Università degli Studi di Roma Tor Vergata - Dipartimento di Medicina dei Sistemi
Drug Survival, long-term efficacy and safety of anti-TNF alpha biosimilar drugs,
Università degli Studi di Roma Tor Vergata - Dipartimento di Medicina dei Sistemi, Italy, New York, United States
Organisation/Company Università degli Studi di Roma Tor Vergata - Dipartimento di Medicina dei Sistemi Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage Researcher (R1) Established Researcher (R3) Country Italy Application Deadline 11 Jan 2026 - 23:59 (UTC) Type of Contract To be defined Job Status Not Applicable Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
Offer Description Main Focus: Cost-effectiveness analysis to quantify avings potential or the National Health Service (NHS). Methodology:Real-World Data Analysis: Use of data from national/regional registersto monitor Drug survival, switch rate and incidence of adverse events on a broad basis patient cohorts.Pharmacoeconomic Models: Development of models to estimate the reduction of spending resulting from the greater adoption of biosimilars (with discountsup to 45% or more, as highlighted in some analyses).Expected Benefits:Better Access: The savings achieved (estimated in hundreds of millions ofeuro/year) can be reallocated to finance new therapies and increase access to biological treatments for more patients.Sustainability: Strengthen confidence in the overlap of effectiveness and safety of biosimilars to ensure the sustainability of the systemlong-term healthcare
Italy
Eligibility of fellows: country/ies of residence: OTHER
Eligibility of fellows: nationality/ies: #J-18808-Ljbffr
Offer Description Main Focus: Cost-effectiveness analysis to quantify avings potential or the National Health Service (NHS). Methodology:Real-World Data Analysis: Use of data from national/regional registersto monitor Drug survival, switch rate and incidence of adverse events on a broad basis patient cohorts.Pharmacoeconomic Models: Development of models to estimate the reduction of spending resulting from the greater adoption of biosimilars (with discountsup to 45% or more, as highlighted in some analyses).Expected Benefits:Better Access: The savings achieved (estimated in hundreds of millions ofeuro/year) can be reallocated to finance new therapies and increase access to biological treatments for more patients.Sustainability: Strengthen confidence in the overlap of effectiveness and safety of biosimilars to ensure the sustainability of the systemlong-term healthcare
Italy
Eligibility of fellows: country/ies of residence: OTHER
Eligibility of fellows: nationality/ies: #J-18808-Ljbffr